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A Comprehensive Report on Marijuana: Focus
on the Paso Del Norte Region

Executive Summary
The present executive summary highlights topics discussed within a
comprehensive and extensive report on marijuana. This condensed summary
discusses the chemical compounds within marijuana, the various methods of
consuming marijuana, the therapeutic effects and health consequences associated
with marijuana use, and repercussions that have emerged as a result of the
legalization of marijuana in many states within the United States. Additionally, the
impact of marijuana in communities within the Paso del Norte Region are
discussed.
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Description of Active Ingredients
Marijuana contains over 400 chemicals
(Lusk & Rutherford, 2017) and
approximately 104 of these chemicals are
cannabinoids (ElSohly and Gul, 2014).
Cannabinoids are molecules that can bind to
cannabinoid receptors in cells (NASEM,
2017). There are two primary cannabinoid
receptors: 1) CB1 which is primarily
expressed in the central nervous system
(Matsuda, Lolait, Brownstein, Young, &
Bonner, 1990), and 2) CB2 which is
primarily expressed in the immune system
(Galiègu et al., 1995). Research on
marijuana has largely focused on examining
CB1 and CB2 receptors in response to two
popular cannabinoids, Delta-9
Tetrahydrocannabinol (THC) and
Cannabidiol (CBD).
Δ9 Tetrahydrocannabinol (THC). THC is
the psychoactive compound within
marijuana that produces the intoxicating
state often referred to as “feeling high.”
This intoxicating state has been described as
“a pleasant euphoria and sense of
relaxation” (National Institute on Drug
Abuse [NIDA], 2018). Furthermore, many
individuals experience increases in appetite,
increases in laughter, heightened sensory
perception (e.g., brighter colors), and altered
perceptions of time (NIDA, 2018).
Importantly, the intoxicating state
accompanying the consumption of THC is
not always pleasant. For example, some
individuals report experiencing heightened
anxiety, panic, and fear. The latter effects
are more common when the individual is
inexperienced or has consumed large or
unexpectedly high potency doses of
marijuana (NIDA, 2018).
Cannabidiol (CBD). CBD is a
cannabinoid that is gaining a great deal of
attention in the last decade because it
contains many of the same therapeutic

properties of THC, however, does not
include the psychoactive components (Izzo,
Borrelli, Capasso, Di Marzo, & Mechoulam,
2009). Thus, individuals can consume CBD
as a treatment without the intoxicating sideeffects; research on CBD has proliferated for
this reason. CBD contains the same
chemical formula as THC but has a minor
difference in the atom arrangement (ElSohly
and Gul, 2014). Scientists believe that the
differences in the atom arrangement
prevents CBD from binding to the receptors
that THC binds to, making CBD nonpsychoactive (ElSohly and Gul, 2014).
Notably, THC and CBD can be extracted
from marijuana and used to create a number
of products such as tinctures/oils (e.g., liquid
substance), topicals (e.g., lotions), and even
edibles (e.g., “weed” brownies).

Methods of Consuming Marijuana
Smoking marijuana is the most common
method of consumption. Marijuana is
typically inserted into a pipe (commonly
referred to as a “bowl”) or rolled cigarette
(commonly referred to as a “joint”) and a
flame is applied so that the marijuana
combusts and releases smoke; the smoke
contains the active ingredients and is
subsequently inhaled. Schauer et al., (2016)
examined a national sample (N = 4,269) of
adults over the age of 18 and reported the
methods of consuming recreational
marijuana in current users (as indexed by
use in past 30 days) was a pipe (49.5%),
joint (49.2%), a bong, water pipe, or hookah
(21.7%), a blunt (20.3%), edibles (16.1%),
and vaporizers (7.6%).
Combusted vs. Ingested THC.
Importantly, combusted (i.e., smoked) THC
affects the body differently than ingested
THC. Specifically, the potency, onset, and
duration of the effects differs depending on
the method in which marijuana is consumed

(Carter, Weydt, Kyashna-Tocha, & Abrams,
2004; Ashton, 2001). For example,
combusted THC is absorbed into the
pulmonary circulation and reverted from the
pulmonary vein back to the heart (Benjamin
& Fossler, 2016). The combusted THC is
subsequently distributed through the
bloodstream systematically, without passing
through the liver (Benjamin & Fossler,
2016). Combusted THC affects the brain
within seconds or minutes and thus
psychoactive effects occur instantaneously
and typically last for one to three hours
(Ashton, 2001).
In contrast, ingested THC is metabolized
by the liver and converted into a chemical

that is much more psychoactive than delta-9
THC, referred to as 11-hydroxy-THC
(Carter, Weydt, Kyashna-Tocha, & Abrams,
2004). Ingested THC may take
approximately 30 minutes to a couple of
hours before the psychoactive effects occur
and the duration of psychoactive effects lasts
longer (Ashton, 2001). Importantly,
cannabinoids are extremely lipid soluble and
thus they accumulate in fatty tissues; the
tissue elimination half-life of THC is
approximately seven days and the complete
elimination of a dose could take up to 30
days (Ashton, 2001). See Table 1 below
for more information about the various
methods of consuming marijuana.

Table 1.
Methods of Consuming Marijuana

Brief Description
Smoking marijuana is the most common method
of consumption.
Involves applying a flame to burn the dry leaves of
marijuana and inhaling the smoke.
Vaporizing marijuana is an emerging method of
consuming marijuana and involves heating dry
cannabis leaves or concentrated THC/CBD oil to a
level high enough to transmit the THC/CBD
without the full combustion that results in smoke.
Vaporizing marijuana has gained popularity
because it is believed to be a healthier option for
consuming marijuana without emitting the
carcinogens, tars, and toxins from combusted
smoke.
Ingesting marijuana edibles involves extracting
THC/CBD from the dry leaves of cannabis and
creating a butter that can be used for cooking or
baking.
Other marijuana pharmacological derivatives:
capsules, spray, tinctures, and topicals are designed
to be absorbed orally or through one’s skin.

Product Description
Pipe: Glass, wood, or metal device that marijuana can be
inserted into and used to inhale smoke.
Bong or bubbler: Glass or plastic device that uses waterfiltration to filter smoke prior to entering the lungs.
Joint: Unfiltered cigarette filled with marijuana.
Blunt: Cigar filled with marijuana.
Desktop Vaporizer: Device that connects to an electrical
wall outlet and allows for the temperature of the heating
device to be adjusted precisely.
Portable Vaporizer: A battery operated device that
allows for mobile use. THC /CBD oils can be combined
with flavors (e.g., cherry) to provide a pleasant taste and
aroma to the vapor that is inhaled and exhaled. Electronic
cigarettes are becoming the most common portable
vaporizer due to their sleek size and discreet appearance.
Candy: Examples of THC/CBD infused candy include
lollipops, gummy bears, and chocolates.
Baked Goods: Common baked goods include brownies,
cookies, and cupcakes. However, it is important to note
that marijuana infused butter can be used to cook/bake any
food or snack that includes butter as an ingredient.
Capsule: Cannabis extract of THC/CBD inserted into a
capsule to be consumed orally.
Tincture: Concentrated THC or CBD cannabis extract
that is applied to specific area of body and absorbed
through one’s skin.

Therapeutic Effects and Health
Consequences
Therapeutic Effects. The National
Academies of Sciences, Engineering and
Medicine (NASEM) released a committee
review in January 2018 examining the health
effects of cannabinoids and concluded that
there is “substantial evidence” suggesting
that marijuana is effective for treating the
following health afflictions: 1) marijuana is
associated with significant reduction in
chronic pain symptoms, 2) oral cannabinoids
are effective antiemetics for treating
chemotherapy-induced vomiting, and 3) oral
cannabinoids are an effective treatment for
multiple sclerosis spasticity symptoms.
Importantly, the NASEM (2017) committee
review concluded that there is “insufficient
or no evidence” that cannabinoids are
associated with reductions in seizure activity
in epileptic patients. Following the NASEM
(2017) committee review, new studies have
emerged suggesting that cannabinoids are
effective at reducing epileptic seizures. For
example, Devinsky et al., (2017) found that
CBD significantly reduced drug-resistant
seizures by 42% in epileptic patients.
Devinsky et al., (2018) found that CBD
reduced the median number of seizures in
epileptic patients by approximately 51% in
12 weeks and 59% in 48 weeks. Tzadok et
al. (2016) examined seventy-four young
children and adolescents (ages 1-18) with
epilepsy who were resistant to 7 or more
antiepileptic drugs and found that nearly 9
out of 10 (89%) patients reported reductions
in seizure activity. These findings
demonstrate unequivocal evidence that
marijuana was not only effective, but also
superior to many of the antiepileptic drugs
currently on the market.

Health Consequences. Major findings
reported within NASEM (2017) suggest that
there is substantial evidence indicating that
the frequency of marijuana use is associated
with: 1) worsened respiratory symptoms and
increases in bronchitis occurrences, 2)
increases in the development of
schizophrenia and other psychoses, and 3)
lower birthrates in offspring exposed to
marijuana while in the womb.

Marijuana Legislation
Repercussions
Within the last two decades, more than
half of the states in the U.S. have legalized
medicinal marijuana use and nine states
(Colorado, Washington, Oregon, Alaska,
California, Nevada, Massachusetts, Maine,
and Vermont) and the District of Columbia
have legalized recreational marijuana use for
individuals who are 21 years of age or older.
The legalization of marijuana has
resulted in a number of unexpected
outcomes. For example, reductions in
opioid related deaths have been reported in
states with liberal marijuana laws
(Livingston, Barnett, Delcher, & Wagenaar,
2017; Powell, Pacula, and Jacobson, 2015;
Hayes & Brown, 2014), reductions in
prescription drugs that marijuana could
serve as a clinical alternative have been
documented in states that have legalized
medicinal marijuana (Bradford & Bradford,
2017), reductions in crimes such as
homicide and assault have been reported in
states that have legalized recreational
marijuana (Morris et al., 2014), increases in
fatal motor vehicle accidents involving
marijuana-positive drivers have been
reported in Colorado (Salomonsen-Sautel et
al., 2014).

Opioids. A national crisis currently
exists in the U.S. due to opioid addiction or
misuse. According to the National Institute
on Drug Abuse (NIDA) more than 115 fatal
over-doses occur daily in the U.S. (NIDA,
2018). Heroin is one of the most common
contributors of fatal opioid related overdoses; however, prescription painkillers are
also addicting and often misused. Powell,
Pacula, and Jacobson (2015) compared
states that have legalized medical marijuana
with states that have not legalized medical
marijuana. The authors reported that states
that have legalized marijuana have also
experienced decreases in both opioid
addictions and opioid overdose deaths
compared to states that have not legalized
medical marijuana. Similarly, Shi (2017)
examined state-level annual administrative
records of hospital discharges during 1997–
2014 and reported that medical marijuana
legalization was associated with 23% (p =
0.008) and 13% (p = 0.025) reductions in
hospitalizations related to opioid
dependence/abuse and the prevalence of
opioid pain reliever overdoses.
Doctors Prescriptions. Another
repercussion following marijuana
legalization is a decrease in prescription
drugs for which marijuana could serve as a
clinical alternative. Specifically, Bradford
and Bradford (2017) examined the
prescriptions filled by Medicare Part D
enrollees from 2010 to 2013 and focused on
prescriptions for health afflictions where
marijuana could serve as a clinical
alternative. Medicare Part D is also referred
to as the Medicare prescription drug benefit
program and was developed to help
beneficiaries pay for prescription drugs
(Medicare, 2018). Notably, after medical
marijuana laws were implemented, there
was a national overall reduction in Medicare
program and enrollee spending estimated to
be $165.2 million per year in 2013. The
authors of the study concluded that the

legalization of marijuana significantly
impacts prescription patterns and spending
in Medicare Part D. Bradford and Bradford
(2017) reported that prescriptions for
painkillers written by doctors reduced by
approximately 1,826 fewer doses (on
average) per year after legalizing marijuana.
Motor Vehicle Accidents. Motor vehicle
crashes are the leading cause of death each
year among young people ages 16-25 years
in the United States (Azofeifa, Mattson, &
Lyerla, 2015). The most frequently detected
substances in fatal car crashes in the U.S. are
alcohol (National Highway Traffic Safety
Administration [NHTSA], 2013) and
marijuana (Brady & Li, 2012). A number of
studies suggest that marijuana use within a
month of driving a motor vehicle is
associated with 2 to 6 times higher risk of
being involved in a motor-vehicle crash
compared to unimpaired drivers (Asbridge,
Hayden, & Cartwright, 2012; Li et al., 2011;
Baldock, 2008; Beirness, Simpson, &
Williams 2006; Ramaekers, Berhaus, van
Laar, & Drummer, 2004; Bates & Blakely,
1999). Research examining the impact of
marijuana legalization on motor vehicle
accidents has yielded conflicting results.
For example, Salomonsen-Sautel et al.,
(2014) examined the proportion of fatal
motor vehicle accidents before and after
legalizing marijuana in Colorado that
involved alcohol-impaired (greater than the
legal limit of 0.08 blood alcohol content)
and marijuana-positive drivers. The results
suggest that after legalizing marijuana in
Colorado there was an increase in fatal
motor vehicle accidents involving
marijuana-positive drivers (p <.0001); there
was no difference in the proportion of motor
vehicle accidents involving marijuanapositive drivers in states that did not legalize
marijuana.
Driving under the influence of
marijuana is associated with decreases in

mean driving speeds, increases in weaving
(within lanes), and increases in average
distances headway to preceding vehicles
(Hartman & Huestis, 2013; Downey et al.,
2013; Bondallaz et al., 2016; Anderson et
al., 2010). However, it is important to note
that a review by Sewell, Poling, and
Sofuoglu (2009) found marijuana use only
had “modest” impairments on actual road
tests. The authors also reported that
experienced marijuana users demonstrated
“almost no functional impairment” under the
influence of marijuana “except when it is
combined with alcohol.” The latter effects
are explained in a number of studies,
highlighting that drivers under the influence
of alcohol tend to underestimate their degree
of impairment; thus, they drive faster,
increase attempts to overtake vehicles, and
decrease their average distance headway to
preceding vehicles (Robbe & O’Hanlon,
1993; Smiley, 1999; Sewell et al., 2009;
Neavyn, Blohm, Babu, & Bird, 2014;
Hartman & Huestis, 2013). In contrast,
drivers under the influence of marijuana
tend to overestimate their degree of
impairment; thus, they driver slower, make
fewer attempts to overtake, and increase
their average distance headway to preceding
vehicles (Robbe & O’Hanlon, 1993; Smiley,
1999; Sewell et al., 2009; Neavyn et al.,
2014; Hartman & Huestis, 2013). Research
suggests that alcohol and marijuana
consumed independently at low doses does
not yield sufficient driving impairments to
rise to the level of a public health or safety
concern, however, driving performance is
dramatically impaired when low doses of the
two substances are consumed
simultaneously (Ramaekers, Robbe, &
O'Hanlon, 2000; Hartman & Huestis, 2013;
Sewell et al., 2009).

Regional Impacts of Marijuana
The Paso del Norte (PdN) region
stretches across two countries and three
states: El Paso and Hudspeth Counties in
Texas, Doña Ana, Luna, and Otero counties
in New Mexico, and the municipality of
Cuidad Juárez, Chihuahua, México. The
impact of legalization in either one of these
states or countries will have consequences
on the region. Currently, none of the
constituents of the PdN region have
legalized recreational marijuana. However,
the national trend toward the legalization of
marijuana may still impact non-legal
marijuana states including those in the PdN
region. For example, Texas has not
legalized recreational or medicinal
marijuana. However, in 2015, The Texas
Compassion Use Act was enacted to allow
patients with intractable epilepsy to access
low-THC cannabis (Texas Department of
Public Safety, 2016). New Mexico became
the twelfth state to allow medical cannabis
with the Lynn and Erin Compassionate Use
Act in 2007 (New Mexico’s Indicator-Based
Information System [NM-IBIS], 2015). The
purpose is to allow the beneficial use of
medical cannabis in a regulated system for
alleviating symptoms caused by debilitating
medical conditions. Most recently,
México’s congress in 2017 approved
medical marijuana use and its
pharmaceutical derivatives (Secretaría de
Gobernacion, 2017). La Secretaría de Salud
is responsible for the development and
enforcement of public policies to regulate
the medical use and upon completion of this
paper, no such plan has been finalized.

Texas and Border Region. The Texas
School Survey of Drug and Alcohol Use
(TSS) assessed current use and attitudes
about licit and illicit drugs in 49,069
students in grades 7-12 from districts across
the state (Texas Department of State Health
Services; DSHS, 2016). The results suggest
that marijuana remains the most widely used
illicit drug among Texas youth, that is,
approximately 20.8% students reported
using marijuana in their lifetime and 12.2%
reported using marijuana in the past-month
preceding the survey. Furthermore, 21.4% of
youth in the border region of Texas (the
study included three districts in El Paso
County) reported using marijuana in their
lifetime and 12.8% reported using marijuana
in the past month. In regards to frequency of
marijuana use, 1.6% of the participants
reported everyday use, 2.0% of the
participants reported several times a week,
2.6% of the participants reported several
times a month, 3.1% of the participants
reported about once a month, and 3.3% of
the participants reported about once a year.
Reports for Region 10 (El Paso County
included) from different law enforcement
agencies report that marijuana and
methamphetamine are the most trafficked
drugs for this area. According to the West
Texas High Intensity Drug Trafficking
Areas (HIDTA), marijuana is currently
priced between $225-$300 per pound in El
Paso (Texas Prevention Resource Center
[TPRC], 2018). Furthermore, CBD
advertisements are proliferating across
storefronts in El Paso. CBD is currently
being sold as gummies, e-liquids, and oils at
convenience stores, smoke shops,
supermarkets with an emphasis on organic
food, and even at pharmacies.
In 2014, there were a total of 30,088
solid pounds of marijuana seized in El Paso,
TX (Texas Prevention Resource Center
[TPRC], 2018). In 2015, there was

approximately 21,543 solid pounds of
marijuana seized in El Paso, TX (TPRC,
2018). In 2016, there was approximately
13,299 pounds of marijuana seized in El
Paso, TX (TPRC, 2018). The latter results
may suggest that the amounts of marijuana
seized in El Paso each year are decreasing.
El Paso County recently approved the
First Chance Program, preventing
individuals from being arrested if they are
caught with less than 4 ounces of marijuana
and it is the first offence (Claster, 2017).
Under the First Chance Program, individuals
who are caught with less than four ounces of
marijuana will have the option to complete
eight hours of community service and pay a
$100 fine. Importantly, if the first time
offender does not complete the program
within 60 days or declines the option to
complete the program, they will be arrested.
New Mexico and Counties. The
prevalence of marijuana use in New Mexico
and surrounding counties is very high.
According to a 2015 survey of 15,624 New
Mexican youth from grades 9-12,
approximately 1 out of 4 students (24.4%,
CI: 23% to 25.9%) reported using marijuana
within the 30 days preceding the survey
(NM-IBIS, 2018). Furthermore,
approximately 1 out of 5 (19.9%, CI: 17.1%
to 23.1%) of youth in Doña Ana County (the
county in closest proximity to El Paso, TX)
reported using marijuana within the 30 days
preceding the survey (NM-IBIS, 2018). In
Otero and Luna Counties, it was reported
that 30.7% and 23.3% of youth used
marijuana in the past 30-days, respectively.
HIDTA reports as of 2018, marijuana
prices range between $240-300 per pound in
Las Cruces, NM (TPRC, 2018). According
to the New Mexico Department of Health
(2018), as of March 31, 2018, there were
50,954 active patients in the Medical
Cannabis Program, purchasing an average
amount of 31.78 units (one unit of usable

cannabis consists of one gram of the dried
leaves and flowers of the female cannabis
plant, or 0.2 grams of THC for cannabisderived products). At the same time point,
Doña Ana County had 3,945 patients, Otero
County had 1,457 patients, and Luna County
299 patients enrolled in the program.
Cd. Juárez, Chihuahua, Mexico. In a
study published in 2016, the marijuana use
among 7th – 12th graders in the state of
Chihuahua was reported at 11.9% lifetime
use (Villatoro Velazquez et al., 2016). In
Cd. Juárez, 12.3% of students in 5th – 12th
grade reported using marijuana, which is
above that of the national rate (Fregoso Ito
et al., 2015).

CONCLUSIONS
The full report includes a comprehensive
review of marijuana to include its history,
composition, methods of consumption,
therapeutic effects and health consequences,
legislation, and the impact of marijuana
legalization in the Paso Del Norte region.
Records indicate that marijuana has been
used for medicinal purposes for thousands of
years. Marijuana contains over 400
chemicals and approximately 104 of these
chemicals are cannabinoids (ElSohly and
Gul, 2014). There are numerous products
created that include cannabinoids (e.g., THC
and CBD) with various forms of
consumption (e.g., edibles, topicals).
Multiple studies support using marijuana or
cannabis-based medications for the
therapeutic effects, however, there are
mixed opinions when addressing the health
consequences. Legalization in some states
have resulted in treatment for substance
abuse, reduction in prescription medications,
and mixed results on crime.
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